BIOGEN INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements
BIOGEN INC. (BIIB) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements of $0 for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-10-21.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilitySettlements · last filed 2020-10-21
- BIOGEN INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2020-09-30 was $0.00.
- BIOGEN INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2020-06-30 was $0.00.
- BIOGEN INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2020-03-31 was $0.00.
- BIOGEN INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for the quarter ending 2019-12-31 was $0.00, a 100.00% decline year-over-year.
- BIOGEN INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2019 was $0.00, a 100.00% decline from fiscal 2018.
- BIOGEN INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2018 was $101.50M, a 1414.93% increase from fiscal 2017.
- BIOGEN INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2017 was $6.70M, a 87.41% decline from fiscal 2016.
- BIOGEN INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, settlements for fiscal 2016 was $53.20M, a 266.90% increase from fiscal 2015.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 3 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 6 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 9 month | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Settlements 12 month |
|---|---|---|---|---|
| 2020-09-30 | $0.00 10-Q · filed 2020-10-21 | $0.00 derived: sum of 2 quarters · filed 2020-10-21 | $0.00 10-Q · filed 2020-10-21 | $0.00 derived: sum of 4 quarters · filed 2020-10-21 |
| 2020-06-30 | $0.00 10-Q · filed 2020-07-22 | $0.00 10-Q · filed 2020-07-22 | $0.00 derived: sum of 3 quarters · filed 2020-07-22 | $0.00 derived: sum of 4 quarters · filed 2020-10-21 |
| 2020-03-31 | $0.00 10-Q · filed 2020-04-23 | $0.00 derived: sum of 2 quarters · filed 2020-04-23 | $0.00 derived: sum of 3 quarters · filed 2020-10-21 | $0.00 derived: sum of 4 quarters · filed 2020-10-21 |
| 2019-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-06 | $0.00 derived: sum of 2 quarters · filed 2020-10-21 | $0.00 derived: sum of 3 quarters · filed 2020-10-21 | $0.00 10-K · filed 2020-02-06 |
| 2019-09-30 | $0.00 10-Q · filed 2020-10-21 | $0.00 derived: sum of 2 quarters · filed 2020-10-21 | $0.00 10-Q · filed 2020-10-21 | $81.50M derived: sum of 4 quarters · filed 2020-10-21 |
| 2019-06-30 | $0.00 10-Q · filed 2020-07-22 | $0.00 10-Q · filed 2020-07-22 | $81.50M derived: sum of 3 quarters · filed 2020-07-22 | $81.50M derived: sum of 4 quarters · filed 2020-07-22 |
| 2019-03-31 | $0.00 10-Q · filed 2020-04-23 | $81.50M derived: sum of 2 quarters · filed 2020-04-23 | $81.50M derived: sum of 3 quarters · filed 2020-04-23 | $81.50M derived: sum of 4 quarters · filed 2020-04-23 |
| 2018-12-31 | $81.50M 10-Q · filed 2019-10-22 | $81.50M derived: sum of 2 quarters · filed 2019-10-22 | $81.50M derived: sum of 3 quarters · filed 2019-10-22 | $101.50M 10-K · filed 2020-02-06 |
| 2018-09-30 | $0.00 10-Q · filed 2019-10-22 | $0.00 derived: sum of 2 quarters · filed 2019-10-22 | $20.00M 10-Q · filed 2019-10-22 | $20.00M derived: sum of 4 quarters · filed 2019-10-22 |
| 2018-06-30 | $0.00 10-Q · filed 2019-07-24 | $20.00M 10-Q · filed 2019-07-24 | $20.00M derived: sum of 3 quarters · filed 2019-07-24 | $20.00M derived: sum of 4 quarters · filed 2019-07-24 |
| 2018-03-31 | $20.00M 10-Q · filed 2019-04-24 | $20.00M derived: sum of 2 quarters · filed 2019-04-24 | $20.00M derived: sum of 3 quarters · filed 2019-04-24 | $20.00M derived: sum of 4 quarters · filed 2019-04-24 |
| 2017-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-06 | $0.00 derived: sum of 2 quarters · filed 2019-02-06 | $0.00 derived: sum of 3 quarters · filed 2019-02-06 | $6.70M 10-K · filed 2019-02-06 |
| 2017-09-30 | $0.00 10-Q · filed 2018-10-23 | $0.00 derived: sum of 2 quarters · filed 2018-10-23 | $6.70M 10-Q · filed 2018-10-23 | $56.70M derived: sum of 4 quarters · filed 2018-10-23 |
| 2017-06-30 | $0.00 10-Q · filed 2018-07-24 | $6.70M 10-Q · filed 2018-07-24 | $56.70M derived: sum of 3 quarters · filed 2018-07-24 | $56.70M derived: sum of 4 quarters · filed 2018-07-24 |
| 2017-03-31 | $6.70M 10-Q · filed 2018-04-24 | $56.70M derived: sum of 2 quarters · filed 2018-04-24 | $56.70M derived: sum of 3 quarters · filed 2018-04-24 | $59.90M derived: sum of 4 quarters · filed 2018-04-24 |
| 2016-12-31 | $50.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-01 | $50.00M derived: sum of 2 quarters · filed 2018-02-01 | $53.20M derived: sum of 3 quarters · filed 2018-02-01 | $53.20M 10-K · filed 2018-02-01 |
| 2016-09-30 | $0.00 10-Q · filed 2017-10-24 | $3.20M derived: sum of 2 quarters · filed 2017-10-24 | $3.20M 10-Q · filed 2017-10-24 | $3.20M derived: sum of 4 quarters · filed 2017-10-24 |
| 2016-06-30 | $3.20M 10-Q · filed 2017-07-25 | $3.20M 10-Q · filed 2017-07-25 | $3.20M derived: sum of 3 quarters · filed 2017-07-25 | $17.70M derived: sum of 4 quarters · filed 2017-07-25 |
| 2016-03-31 | $0.00 10-Q · filed 2017-04-25 | $0.00 derived: sum of 2 quarters · filed 2017-04-25 | $14.50M derived: sum of 3 quarters · filed 2017-04-25 | $14.50M derived: sum of 4 quarters · filed 2017-04-25 |
| 2015-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-02 | $14.50M derived: sum of 2 quarters · filed 2017-02-02 | $14.50M derived: sum of 3 quarters · filed 2017-02-02 | $14.50M 10-K · filed 2017-02-02 |
| 2015-09-30 | $14.50M 10-Q · filed 2016-10-26 | $14.50M derived: sum of 2 quarters · filed 2016-10-26 | $14.50M 10-Q · filed 2016-10-26 | $19.50M derived: sum of 4 quarters · filed 2016-10-26 |
| 2015-06-30 | $0.00 10-Q · filed 2016-07-21 | $0.00 10-Q · filed 2016-07-21 | $5.00M derived: sum of 3 quarters · filed 2016-07-21 | $21.50M derived: sum of 4 quarters · filed 2016-07-21 |
| 2015-03-31 | $0.00 10-Q · filed 2016-04-21 | $5.00M derived: sum of 2 quarters · filed 2016-04-21 | $21.50M derived: sum of 3 quarters · filed 2016-04-21 | $21.50M derived: sum of 4 quarters · filed 2016-04-21 |
| 2014-12-31 | $5.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-03 | $21.50M derived: sum of 2 quarters · filed 2016-02-03 | $21.50M derived: sum of 3 quarters · filed 2016-02-03 | $26.50M 10-K · filed 2016-02-03 |
| 2014-09-30 | $16.50M 10-Q · filed 2015-10-21 | $16.50M derived: sum of 2 quarters · filed 2015-10-21 | $21.50M 10-Q · filed 2015-10-21 | $24.10M derived: sum of 4 quarters · filed 2015-10-21 |
| 2014-06-30 | $0.00 10-Q · filed 2015-07-24 | $5.00M 10-Q · filed 2015-07-24 | $7.60M derived: sum of 3 quarters · filed 2015-07-24 | $7.50M derived: sum of 4 quarters · filed 2015-07-24 |
| 2014-03-31 | $5.00M 10-Q · filed 2015-04-24 | $7.60M derived: sum of 2 quarters · filed 2015-04-24 | $7.50M derived: sum of 3 quarters · filed 2015-04-24 | $15.00M derived: sum of 4 quarters · filed 2015-04-24 |
| 2013-12-31 | $2.60M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-04 | $2.50M derived: sum of 2 quarters · filed 2015-02-04 | $10.00M derived: sum of 3 quarters · filed 2015-02-04 | $12.50M 10-K · filed 2015-02-04 |
| 2013-09-30 | -$100.00K 10-Q · filed 2014-10-22 | $7.40M derived: sum of 2 quarters · filed 2014-10-22 | $9.90M 10-Q · filed 2014-10-22 | $9.90M derived: sum of 4 quarters · filed 2014-10-22 |
| 2013-06-30 | $7.50M 10-Q · filed 2014-07-23 | $10.00M 10-Q · filed 2014-07-23 | $10.00M derived: sum of 3 quarters · filed 2014-07-23 | $10.00M derived: sum of 4 quarters · filed 2014-07-23 |
| 2013-03-31 | $2.50M 10-Q · filed 2014-04-23 | $2.50M derived: sum of 2 quarters · filed 2014-04-23 | $2.50M derived: sum of 3 quarters · filed 2014-04-23 | $9.00M derived: sum of 4 quarters · filed 2014-04-23 |
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-02-06 | $0.00 derived: sum of 2 quarters · filed 2014-02-06 | $6.50M derived: sum of 3 quarters · filed 2014-02-06 | $6.50M 10-K · filed 2014-02-06 |
| 2012-09-30 | $0.00 10-Q · filed 2013-10-28 | $6.50M derived: sum of 2 quarters · filed 2013-10-28 | $6.50M 10-Q · filed 2013-10-28 | |
| 2012-06-30 | $6.50M 10-Q · filed 2013-07-25 | $6.50M 10-Q · filed 2013-07-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |